Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.81 |
| ▸ | PTK2 | Q05397 | 18/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816287 | 0.90 | LRRK2 (0.78) | LRRK2PTK2 | |
| SCHEMBL7449659 | 0.90 | LRRK2 (1.00) | LRRK2PTK2AURKAAURKB | |
| SCHEMBL1532262 | 0.89 | LRRK2 (0.76) | LRRK2PTK2 | |
| SCHEMBL12628004 | 0.89 | BRD4 (0.73) | LRRK2PTK2AURKAAURKB | |
| SCHEMBL12657058 | 0.88 | LRRK2 (0.75) | LRRK2PTK2 | |
| SCHEMBL13191369 | 0.86 | LRRK2 (0.81) | LRRK2PTK2 | |
| SCHEMBL1376283 | 0.86 | LRRK2 (0.80) | LRRK2PTK2 | |
| SCHEMBL1466058 | 0.85 | LRRK2 (0.77) | LRRK2PTK2AURKAAURKB | |
| SCHEMBL1465993 | 0.85 | LRRK2 (0.77) | LRRK2PTK2AURKAAURKB | |
| SCHEMBL1466032 | 0.85 | LRRK2 (0.81) | LRRK2PTK2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | LRRK2 574/4885PTK2 66/4885AURKA 31/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | LRRK2 574/4885PTK2 66/4885AURKA 31/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | LRRK2 572/4885PTK2 71/4885AURKA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.